

Amended Claims (Attorney Docket No. 0272US310)

---

1. (Currently amended) A variant of ~~FVII~~ Factor VII (FVII) or ~~FVIIa~~ Factor VIIa (FVIIa), wherein said variant comprises 1-15 amino acid modifications as compared to hFVII or hFVIIa (SEQ ID NO:2), ~~including wherein at least one amino acid modification in a position selected from the group consisting of positions 196, 237 and 341,~~ comprises a substitution, wherein the substitution is D196K as compared to SEQ ID NO:2,
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Currently amended) The variant of claim 1, wherein said variant further comprises a modification in position 237 as compared to hFVII or hFVIIa (SEQ ID NO:2).
7. (Original) The variant of claim 6, wherein said modification is a substitution.
8. (Original) The variant of claim 7, wherein said substitution is G237L.
9. (Original) The variant of claim 6, wherein said modification is an insertion.
10. (Original) The variant of claim 9, wherein said insertion is selected from the group consisting of G237GXX, G237GXXX and G237GXXXX, wherein X is any amino acid residue.
11. (Currently amended) The variant of claim 10, wherein X is selected from the group consisting of Ala, Val, Leu, Ile, Gly, Ser and Thr.

12. (Original) The variant of claim 11, wherein X is Ala.
13. (Previously presented) The variant of claim 12, wherein said insertion is G237GAA.
14. (Previously presented) The variant of claim 1, wherein said variant comprises a modification in position 341 as compared to hFVII or hFVIIa (SEQ ID NO:2).
15. (Original) The variant of claim 14, wherein said modification is a substitution.
16. (Original) The variant of claim 15, wherein said substitution is K341Q.
17. (Canceled)
- 18-53. (Canceled)
54. (Previously presented) The variant of claim 1, wherein said variant is in its activated form.
55. (Previously presented) A nucleotide sequence encoding a variant as defined in claim 1.
56. (Original) An expression vector comprising a nucleotide sequence as defined in claim 55.
57. (Previously presented) A host cell comprising an expression vector as defined in claim 56.
58. (Original) The host cell of claim 57, wherein said host cell is a gamma-carboxylating cell capable of *in vivo* glycosylation.
59. (Previously presented) A composition comprising a variant as defined in claim 1 and at least one pharmaceutically acceptable carrier or excipient.
- 60-64. (Canceled)

65. (Previously presented) A method for treating a mammal having a disease or disorder wherein clot formation is desirable, comprising administering to a mammal in need thereof an effective amount of the variant of claim 1.

66. (Original) The method of claim 65, wherein said disease or disorder is selected from the group consisting of hemorrhages, including brain hemorrhages, sever uncontrolled bleedings, such as trauma, bleedings in patients undergoing transplantations or resection, variceal bleedings, and hemophilia.

67. (Original) The method of claim 66, wherein said disease or disorder is trauma.

68. (Original) The method of claim 66, wherein said disease or disorder is hemophilia.